DE69826132D1 - Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption - Google Patents

Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption

Info

Publication number
DE69826132D1
DE69826132D1 DE69826132T DE69826132T DE69826132D1 DE 69826132 D1 DE69826132 D1 DE 69826132D1 DE 69826132 T DE69826132 T DE 69826132T DE 69826132 T DE69826132 T DE 69826132T DE 69826132 D1 DE69826132 D1 DE 69826132D1
Authority
DE
Germany
Prior art keywords
parathormone
inhibitor
bone resorption
pharmaceutical combination
parathyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826132T
Other languages
English (en)
Other versions
DE69826132T2 (de
Inventor
John Dietrich
Sverker Ljunghall
Sven Sjoegren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Allelix Corp Canada filed Critical NPS Allelix Corp Canada
Application granted granted Critical
Publication of DE69826132D1 publication Critical patent/DE69826132D1/de
Publication of DE69826132T2 publication Critical patent/DE69826132T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
DE69826132T 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption Expired - Lifetime DE69826132T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use
SE9702401 1997-06-19
PCT/SE1998/001095 WO1998057656A1 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor

Publications (2)

Publication Number Publication Date
DE69826132D1 true DE69826132D1 (de) 2004-10-14
DE69826132T2 DE69826132T2 (de) 2005-09-15

Family

ID=20407482

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69826132T Expired - Lifetime DE69826132T2 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
DE69841279T Expired - Lifetime DE69841279D1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69841279T Expired - Lifetime DE69841279D1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon

Country Status (15)

Country Link
US (8) US6284730B1 (de)
EP (2) EP1473040B1 (de)
JP (3) JP4989811B2 (de)
AT (2) ATE275419T1 (de)
AU (1) AU753477B2 (de)
CA (2) CA2698626C (de)
CY (1) CY1110287T1 (de)
DE (2) DE69826132T2 (de)
DK (2) DK1473040T3 (de)
ES (2) ES2335404T3 (de)
HK (2) HK1029738A1 (de)
PT (2) PT1001802E (de)
SE (1) SE9702401D0 (de)
WO (1) WO1998057656A1 (de)
ZA (1) ZA984947B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
CN101837120A (zh) 2001-06-01 2010-09-22 诺瓦提斯公司 口服施用甲状旁腺激素和降钙素
ATE285756T1 (de) * 2001-06-28 2005-01-15 Microchips Inc Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
PT1656372E (pt) * 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
WO2005046798A1 (en) * 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
EP1843783B1 (de) 2005-01-25 2012-05-30 MicroCHIPS, Inc. Steuerung der wirkstofffreisetzung mittels transienter modifizierung lokaler mikroumgebungen
EP1896134A2 (de) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung degenerativer knochenerkrankungen
ATE352714T1 (de) * 2005-06-17 2007-02-15 Magneti Marelli Powertrain Spa Brennstoffeinspritzventil
EP1945245A2 (de) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
KR102335703B1 (ko) * 2009-09-09 2021-12-07 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
EP2790710B1 (de) * 2011-12-13 2020-08-26 Amorphical Ltd. Amorphes calciumcarbonat zur behandlung von calciumabsorptionsstörungen und knochenstoffwechselstörungen
CN107921060A (zh) 2015-06-04 2018-04-17 艾玛菲克有限公司 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物
US11052108B2 (en) 2016-10-25 2021-07-06 Amorphical Ltd. Amorphous calcium carbonate for treating a leukemia

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) * 1972-08-02 1973-10-30 R Thomas Educational device
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) * 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4199060A (en) * 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4425437A (en) * 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4383066A (en) 1980-04-15 1983-05-10 Mitsubishi Gas Chemical Company, Inc. Polyphenylene ether resin composition
JPS5825439B2 (ja) 1980-12-30 1983-05-27 株式会社林原生物化学研究所 ヒト副甲状腺ホルモンの製造方法
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
NO163060C (no) 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
US4385212A (en) 1981-10-05 1983-05-24 Bell Telephone Laboratories Incorporated Expandable communication terminal housing
US4424278A (en) * 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4595658A (en) * 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
WO1984001173A1 (en) 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
DE3312928A1 (de) 1983-04-11 1984-11-22 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Human-parathormon produzierende hybridvektoren und human-parathormongen
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
US4637980A (en) 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0205475B2 (de) 1984-12-06 2002-09-04 Amgen Inc. Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IE67035B1 (en) 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5010010A (en) * 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
WO1988003171A1 (en) 1986-10-30 1988-05-05 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
FI77278C (fi) 1986-10-31 1989-02-10 Ahlstroem Oy Foerfarande och anordning foer foerbraenning av sodasvartlut.
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
FR2618914B1 (fr) 1987-07-31 1991-12-06 Alain Souloumiac Perfectionnements apportes aux interrupteurs optomagnetiques
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
WO1989004173A1 (en) 1987-11-12 1989-05-18 Schering Corporation Acceleration of bone formation with gm-csf
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5171670A (en) * 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
USRE37919E1 (en) * 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0559751B1 (de) * 1990-11-26 1997-03-26 RECKER, Robert R. Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
KR0131678B1 (ko) 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
EP0618805A1 (de) 1991-12-17 1994-10-12 PROCTER & GAMBLE PHARMACEUTICALS, INC. Methoden zur behandlung von osteoporose unter verwendung von biphosphonaten und parathormon
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW303299B (de) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
CN1157565A (zh) * 1994-09-09 1997-08-20 普罗克特和甘保尔公司 用骨活性膦酸盐和甲状旁腺激素治疗骨质疏松症的方法
JP2001503728A (ja) 1994-09-09 2001-03-21 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症治療用のエストロゲン及び副甲状腺ホルモン
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5550134A (en) 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use

Also Published As

Publication number Publication date
US8153588B2 (en) 2012-04-10
CA2294101C (en) 2010-08-03
US20030162716A1 (en) 2003-08-28
EP1001802B1 (de) 2004-09-08
JP5525825B2 (ja) 2014-06-18
US7018982B2 (en) 2006-03-28
JP2010100644A (ja) 2010-05-06
US20120148684A1 (en) 2012-06-14
US7507715B2 (en) 2009-03-24
DE69826132T2 (de) 2005-09-15
HK1029738A1 (en) 2001-04-12
HK1070816A1 (en) 2005-06-30
EP1473040B1 (de) 2009-11-04
CY1110287T1 (el) 2015-01-14
PT1473040E (pt) 2010-02-02
DK1473040T3 (da) 2010-03-15
AU753477B2 (en) 2002-10-17
US20090118192A1 (en) 2009-05-07
ES2335404T3 (es) 2010-03-26
DK1001802T3 (da) 2005-01-17
CA2294101A1 (en) 1998-12-23
ZA984947B (en) 1999-01-04
CA2698626C (en) 2016-02-09
PT1001802E (pt) 2005-01-31
ATE275419T1 (de) 2004-09-15
US20140256632A1 (en) 2014-09-11
US20020002135A1 (en) 2002-01-03
SE9702401D0 (sv) 1997-06-19
JP4989811B2 (ja) 2012-08-01
US7749543B2 (en) 2010-07-06
WO1998057656A1 (en) 1998-12-23
CA2698626A1 (en) 1998-12-23
ES2229511T3 (es) 2005-04-16
US20060211613A1 (en) 2006-09-21
AU7945898A (en) 1999-01-04
JP2002504140A (ja) 2002-02-05
US6284730B1 (en) 2001-09-04
EP1001802A1 (de) 2000-05-24
JP2014015479A (ja) 2014-01-30
US8765674B2 (en) 2014-07-01
US20110071081A1 (en) 2011-03-24
DE69841279D1 (de) 2009-12-17
EP1473040A1 (de) 2004-11-03
ATE447410T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
ATE104854T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose.
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
ATE285237T1 (de) Zusammensetzung die tramadol und ein nichtsteroides entzündungshemmenden mittel enthält
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE162073T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose enthaltend xanthohumol
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
KR930021178A (ko) 뼈 형성을 자극하는 약제
ATE205716T1 (de) Hormonales mittel zur therapie der akne und dessen verwendung
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
TH19526A (th) วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NPS ALLELIX CORP., TORONTO, ONTARIO, CA

8327 Change in the person/name/address of the patent owner

Owner name: NPS PHARMACEUTICALS,INC., BEDMINSTER, N.J., US

8380 Miscellaneous part iii

Free format text: DINGLICHES RECHT WURDE BESTELLT